nct02605785-tau-pet-psp

Molecular Anatomic Imaging Analysis of Tau in PSP

Overview

The Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy (NCT02605785) is an active imaging study investigating tau burden in the brains of PSP patients using advanced PET imaging techniques. This study represents a critical effort to characterize the spatial distribution, magnitude, and clinical correlates of tau pathology in vivo, providing essential insights into disease pathogenesis and enabling the development of tau-targeted therapeutics.

Tau PET imaging has revolutionized our ability to visualize protein pathology in living patients. While historically limited to post-mortem neuropathological examination, modern tau PET tracers allow researchers and clinicians to observe the distribution and progression of tau deposits in the living brain. In PSP, this capability is particularly valuable because tau pathology is the defining neuropathological feature of the disease, and understanding its in vivo distribution is crucial for diagnosis, prognosis, and therapeutic development.

Trial Information

| Field | Value |
|-------|-------|
| NCT ID | NCT02605785 |
| Status | Recruiting |
| Condition | Progressive Supranuclear Palsy |
| Category | Neuroimaging / Tau PET |
| Study Type | Observational |
| Clinicaltrials.gov | [NCT02605785](https://clinicaltrials.gov/study/NCT02605785) |

Study Objectives

Primary Goals

The study aims to comprehensively characterize tau burden in PSP patients through:

Molecular Anatomic Imaging Analysis of Tau in PSP

Overview

The Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy (NCT02605785) is an active imaging study investigating tau burden in the brains of PSP patients using advanced PET imaging techniques. This study represents a critical effort to characterize the spatial distribution, magnitude, and clinical correlates of tau pathology in vivo, providing essential insights into disease pathogenesis and enabling the development of tau-targeted therapeutics.

Tau PET imaging has revolutionized our ability to visualize protein pathology in living patients. While historically limited to post-mortem neuropathological examination, modern tau PET tracers allow researchers and clinicians to observe the distribution and progression of tau deposits in the living brain. In PSP, this capability is particularly valuable because tau pathology is the defining neuropathological feature of the disease, and understanding its in vivo distribution is crucial for diagnosis, prognosis, and therapeutic development.

Trial Information

| Field | Value |
|-------|-------|
| NCT ID | NCT02605785 |
| Status | Recruiting |
| Condition | Progressive Supranuclear Palsy |
| Category | Neuroimaging / Tau PET |
| Study Type | Observational |
| Clinicaltrials.gov | [NCT02605785](https://clinicaltrials.gov/study/NCT02605785) |

Study Objectives

Primary Goals

The study aims to comprehensively characterize tau burden in PSP patients through:

• Motor symptoms (postural instability, vertical gaze palsy, bradykinesia)
• Cognitive impairment (executive dysfunction, behavioral changes)
• Disease severity and duration

Secondary Objectives

• Disease Progression Biomarkers: Establish whether tau PET signal correlates with disease progression rate, potentially enabling prediction of clinical course.
• Therapeutic Target Validation: Provide data to support anti-tau therapeutic development by confirming target engagement and demonstrating that tau burden can be modulated.
• Differential Diagnosis: Refine the diagnostic utility of tau PET for distinguishing PSP from other parkinsonian disorders, particularly Parkinson's disease, corticobasal syndrome, and multiple system atrophy.

Scientific Context

Tau PET Imaging in PSP

Tau PET imaging has emerged as a critical tool for visualizing tau pathology in vivo. Unlike amyloid PET, where multiple FDA-approved tracers exist, tau PET tracers have been developed more recently and continue to evolve[@tau_pet_methods]. Key tracers used in PSP research include:

Available Tracers

| Tracer | Target | Specificity | Status |
|--------|--------|-------------|--------|
| [18F]PI-2620 | 4R tau | 4R-selective | Research |
| [18F]AV-1451 (Flortaucipir) | PHF tau | 3R/4R (prefers AD-type) | Research |
| [18F]MNI-958 | 4R tau | 4R-selective | Research |
| [18F]PM-PBB3 | PHF tau | 3R/4R | Research |

4R-Tau Selective Tracers

Traditional tau PET tracers like flortaucipir were developed for Alzheimer's disease and show high affinity for the paired helical filament (PHF) tau found in AD. However, PSP is characterized by different tau filament structures—predominantly straight filaments composed of 4-repeat (4R) tau isoforms. This structural difference limits the binding of some traditional tracers to PSP tau pathology[@4r_tracers].

Novel tracers specifically designed for 4R tauopathies, such as PI-2620, show improved binding to PSP tau deposits. These 4R-selective tracers bind to the distinct conformations of 4R tau filaments, enabling more sensitive detection of tau pathology in PSP patients.

Tau Pathology in PSP

Progressive Supranuclear Palsy is classified as a 4-repeat (4R) tauopathy, meaning it is characterized by accumulation of tau protein isoforms containing four microtubule-binding repeats. This distinguishes PSP from Alzheimer's disease, which involves both 3R and 4R tau, and from Pick's disease, which involves only 3R tau.

Affected Brain Regions

In PSP, 4R tau accumulates in specific anatomical regions[@psp_tau_distribution]:

Subcortical Structures:

• Globose basal ganglia neurons: The most severely affected population, particularly in the globus pallidus
• Subthalamic nucleus: Very early and severe involvement[@subthalamic_nucleus]
• Brainstem nuclei: Substantia nigra, red nucleus, oculomotor nucleus
• Cerebellar nuclei: Dentate nucleus and other cerebellar nuclei

• Motor and premotor cortex (in some variants)
• Frontal cortex (particularly in PSP with cortical involvement)

• Neurons: Primary tau accumulation in neurons, particularly in subcortical nuclei
• Astrocytes: Tufted astrocytes with tau pathology (a PSP hallmark)[@astrocytic_taupathy]
• Oligodendrocytes: Oligodendroglial tau coils[@oligodendroglial_tau]

Tau Strain Diversity

Emerging evidence suggests that tau aggregates in PSP may exist as distinct "strains" with different conformational properties[@tau_strains]. These strain differences may explain:

• Variable clinical presentations
• Differential tracer binding
• Potential for different propagation mechanisms

Understanding Selective Neuronal Vulnerability

One of the most intriguing aspects of PSP is the selective vulnerability of specific neuronal populations. Certain brain regions and cell types are preferentially affected, while others are relatively spared. Tau PET imaging provides an in vivo window into this selective vulnerability[@selective_vulnerability].

Vulnerable Regions

• Subthalamic nucleus: Among the earliest and most affected regions
• Globus pallidus internus: Severe tau burden
• Brainstem nuclei: Severe involvement
• Certain cortical pyramidal neurons: Variable involvement

Relatively Spared Regions

• Hippocampus: Much less affected than in AD
• Posterior cingulate: Relatively spared
• Sensory and visual cortices: Generally spared

Imaging Methodology

PET Acquisition and Processing

The study employs standardized PET imaging protocols:

Image Acquisition:

• 90-minute dynamic PET acquisition following tracer injection
• Attenuation correction using CT or transmission scans
• Reconstruction with ordered subset expectation maximization (OSEM)

• Motion correction for head movement during acquisition
• Frame-to-frame alignment
• Co-registration to structural MRI for precise region-of-interest definition
• Partial volume correction to account for limited spatial resolution

Quantification Approaches

Tau PET data are quantified using several approaches:

Reference Region Selection

Choice of reference region is critical for PSP tau PET:

Cerebellar Gray Matter: Commonly used as reference, assuming relatively low tau pathology in this region. However, some tau accumulation occurs in cerebellar nuclei in PSP.

Cortical Reference: Some studies use mean cortical uptake as reference.

White Matter: Sometimes used, but may contain tau in PSP.

Clinical Correlates and Significance

Tau Burden and Clinical Features

Tau PET imaging enables investigation of the relationship between tau pathology and clinical manifestations[@clinical_trials_taupet]:

Motor Symptoms

• Postural instability: Correlation with globus pallidus and subthalamic nucleus tau
• Vertical gaze palsy: Correlation with brainstem tau burden
• Bradykinesia: Associations with basal ganglia tau

Cognitive Impairment

• Executive dysfunction: Correlation with prefrontal cortex and caudate tau
• Behavioral changes: Associations with frontal and limbic system tau
• Dementia severity: Overall tau burden correlates with global cognitive impairment

Diagnostic Utility

Tau PET has significant diagnostic value in differentiating parkinsonian disorders[@diagnostic_accuracy]:

| Pattern | PSP | PD | MSA | CBS |
|---------|-----|----|----|----|
| Basal ganglia uptake | High | Low | Moderate | Moderate |
| Brainstem uptake | High | Low | Moderate | Variable |
| Cortical uptake | Low-moderate | Very low | Very low | Moderate |
| Pattern distinction | Subcortical | Minimal | Variable | Asymmetric |

Disease Progression

Longitudinal tau PET studies demonstrate that tau burden increases over time in PSP[@longitudinal]. The rate of tau accumulation correlates with:

• Clinical progression rate
• Development of new symptoms
• Conversion from mild to severe disease stages

• Tracking disease progression
• Monitoring therapeutic efficacy
• Enriching clinical trials with rapidly progressing patients

Clinical Significance

This imaging study contributes to understanding the spatial distribution of tau pathology in PSP, which is essential for:

1. Diagnostic Accuracy

Tau PET provides objective, in vivo evidence of tau pathology, supporting clinical diagnosis. This is particularly valuable in:

• Early disease stages when clinical features are less specific
• Distinguishing PSP from other parkinsonian disorders
• Identifying atypical presentations

2. Disease Monitoring

Tau PET enables non-invasive monitoring of disease progression:

• Quantifies rate of tau accumulation
• Identifies regions of most rapid progression
• Provides objective measures for clinical trials

3. Therapeutic Development

The study supports anti-tau therapeutic development by:

• Validating tau as a therapeutic target
• Enabling patient selection based on tau burden
• Providing biomarkers for target engagement
• Monitoring treatment effects on tau pathology[@therapy_monitoring]

4. Understanding Pathogenesis

Tau PET data illuminate disease mechanisms:

• Selective neuronal vulnerability patterns
• Tau propagation along neural circuits[@propagation]
• Relationship between tau and clinical symptoms

Related Mechanisms and Pathways

Tau Pathology in 4R Tauopathies

The molecular mechanisms underlying tau pathology in PSP involve:

Key Pathways

• [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway)
• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [PSP Tau Aggregate Specificity](/mechanisms/psp-tau-aggregate-specificity)
• [Tau Propagation in PSP](/mechanisms/tau-propagation-psp)
• [PSP Neuropathology](/mechanisms/psp-neuropathology)

Regional Vulnerabilities

• [Basal Ganglia in PSP](/brain-regions/basal-ganglia)
• [Subthalamic Nucleus](/brain-regions/subthalamic-nucleus)
• [Brainstem Nuclei](/brain-regions/brainstem)
• [Cerebellar Nuclei](/brain-regions/cerebellum)

Related Pages

• [Tau PET in CBS/PSP](/biomarkers/tau-pet-cbs-psp)
• [PI-2620 Tau PET in PSP](/clinical-trials/pi2620-psp-tau-pet)
• [Tau Pathology in PSP](/mechanisms/psp-tau-aggregate-specificity)
• [Progressive Supranuclear Palsy Neuropathology](/mechanisms/psp-neuropathology)
• [PSP Overview](/diseases/psp-overview)
• [Biomarkers for PSP](/biomarkers/psp-biomarkers)
• [4R Tauopathies Overview](/mechanisms/4r-tauopathies-overview)

See Also

• [Alzheimer's Disease - Tau PET](/biomarkers/tau-pet-imaging)
• [Parkinson's Disease - Neuroimaging](/biomarkers/psp-neuroimaging)
• [Corticobasal Syndrome - Tau PET](/biomarkers/cbs-psp-imaging-biomarkers)

External Links

• [ClinicalTrials.gov - NCT02605785](https://clinicaltrials.gov/study/NCT02605785)
• [PubMed - Tau PET in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=tau+PET+PSP)
• [ACTRN - PSP Tau Imaging](https://www.ncbi.nlm.nih.gov/pmc/)

References

Technical Considerations and Challenges

Partial Volume Effect

A significant challenge in tau PET imaging is the partial volume effect (PVE), which causes underestimation of tracer uptake in small structures due to the limited spatial resolution of PET. This is particularly problematic for PSP, where affected structures like the subthalamic nucleus are relatively small.

Solutions implemented in the study:

• Co-registration with high-resolution MRI for precise anatomical localization
• Partial volume correction algorithms that account for regional atrophy
• Regional analysis focusing on larger structures where PVE is less severe

Off-Target Binding

Many tau PET tracers show off-target binding to structures other than tau aggregates:

Common off-target sites:

• Neuromelanin in substantia nigra
• Monoamine oxidase in basal ganglia
• Calcification in blood vessels
• Bone uptake (from free radioactive tracer)

Comparison Across Tracers

Different tau PET tracers show varying sensitivity to PSP tau pathology:

| Tracer | 4R Tau Sensitivity | Off-Target Issues | Clinical Utility |
|--------|-------------------|-------------------|------------------|
| PI-2620 | High | Moderate (MAOs) | Good for PSP |
| Flortaucipir | Low-Moderate | Neuromelanin | Limited for PSP |
| PM-PBB3 | Moderate | Blood pool | Moderate for PSP |
| MNI-958 | High | Under investigation | Promising |

Reproducibility and Standardization

Ensuring reproducible results across scanner types, sites, and time points is critical:

Quality Control Measures:

• Regular phantom-based calibration
• Inter-site calibration protocols
• Standardized acquisition and processing protocols
• Ongoing scanner performance monitoring

Comparison with Other Neurodegenerative Disorders

Alzheimer's Disease

Tau PET in AD shows distinct patterns from PSP:

| Feature | PSP | AD |
|---------|-----|-----|
| Primary region | Subcortical (basal ganglia, brainstem) | Cortical (entorhinal, temporal) |
| Hippocampus | Relatively spared | Severely affected |
| Pattern | "Subcortical predominant" | "Cortical predominant" |
| Severity | Lower SUVR overall | Higher SUVR in affected regions |

Parkinson's Disease

Primary tau PET signal in PD is minimal, as PD is primarily an alpha-synucleinopathy:

• Basal ganglia tau signal in PD typically reflects incidental AD-type pathology
• True PD-related tau PET signal is very low
• This contrast helps distinguish PSP from advanced PD

Corticobasal Syndrome

CBS shares features with both PSP and AD:

• Asymmetric cortical and basal ganglia involvement
• Can show AD-type or PSP-type tau patterns
• Tau PET helps identify underlying pathology

Multiple System Atrophy

MSA primarily involves alpha-synuclein in oligodendrocytes:

• Tau PET signal is generally lower than in PSP
• Different pattern (more posterior putaminal)
• Distinction based on combination of imaging and clinical features

Future Directions and Applications

Emerging Tracers

Next-generation tau PET tracers in development include:

More 4R-Selective Tracers:

• Improved binding to 4R tau filaments
• Reduced off-target binding
• Better quantification of PSP pathology

• Targeting soluble tau oligomers rather than fibrillar tau
• May provide earlier detection
• More closely linked to toxic species

• Reduced background signal
• Earlier image acquisition
• Better signal-to-noise ratio

Multi-Modal Imaging Integration

Combining tau PET with other imaging modalities provides complementary information:

MRI:

• Structural atrophy patterns
• Diffusion tensor imaging (DTI) for white matter integrity
• Functional connectivity

• Excludes AD co-pathology
• Clarifies mixed pathology cases

• Hypometabolism patterns
• Correlates with tau burden

• Neuroinflammation markers (TSPO PET)
• Monoamine oxidase activity

Quantitative Approaches

Advanced quantification methods under development:

Machine Learning:

• Automated region-of-interest definition
• Pattern recognition for differential diagnosis
• Predictive models for clinical progression

• Network-based analysis of tau spreading
• Connectivity-informed models
• Personalized tau burden mapping

Clinical Trial Applications

Tau PET is increasingly used in clinical trials:

Patient Selection:

• Enriching trials with patients showing sufficient tau pathology
• Excluding patients with minimal tau (unlikely to benefit)
• Stratifying by baseline tau burden

• Primary or secondary endpoints in anti-tau therapy trials
• Dose-finding based on target engagement
• Monitoring treatment effects on tau accumulation

• Demonstrating modification of underlying pathology
• Correlating biomarker changes with clinical outcomes
• Supporting regulatory approval

Tau PET in Clinical Practice

Current Clinical Utility

While primarily a research tool, tau PET has emerging clinical applications:

Differential Diagnosis:

• Supporting PSP diagnosis in challenging cases
• Distinguishing from other parkinsonian disorders
• Identifying AD co-pathology in PSP patients

• Predicting disease progression rate
• Anticipating clinical outcomes
• Guiding management decisions

• Tracking disease progression
• Evaluating treatment effects (in research settings)
• Informing clinical decisions

Barriers to Clinical Implementation

Several factors limit widespread clinical use:

• Limited availability of specialized centers
• High cost of imaging
• Lack of standardized protocols
• Insurance coverage issues
• Need for specialized expertise in interpretation

Future Clinical Adoption

As the field advances, tau PET may become more clinically accessible:

• Development of simplified quantification methods
• Standardization across sites
• FDA approval of specific tracers for clinical use
• Integration into diagnostic algorithms

Conclusion

The Molecular Anatomic Imaging Analysis of Tau in PSP represents a critical scientific endeavor that advances our understanding of tau pathology in living patients. By characterizing the in vivo distribution, magnitude, and clinical correlates of tau burden in PSP, this study provides essential insights into disease pathogenesis while supporting the development of tau-targeted therapeutics.

The study's findings will inform:

• Improved diagnostic accuracy for PSP
• Better understanding of selective neuronal vulnerability
• Development of disease-modifying therapies targeting tau
• Monitoring of treatment effects in clinical trials

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
• [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving nct02605785-tau-pet-psp discovered through SciDEX knowledge graph analysis: